Can a common statin tame cirrhosis complications?
NCT ID NCT05563389
First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time
Summary
Researchers are testing whether atorvastatin, a widely used cholesterol drug, can reduce complications in people with decompensated liver cirrhosis. The trial enrolls 100 adults aged 18 to 75 who have had at least one serious cirrhosis complication, such as ascites, jaundice, or bleeding. Participants receive either atorvastatin 20 mg or a placebo, and the team tracks changes in complications and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- atorvastatin, a common cholesterol-lowering statin
- What this could lead to
- If it works, atorvastatin could become a low-cost way to reduce repeat complications and improve daily life for people with decompensated cirrhosis.
- What could go wrong
- This is a mid-stage trial in 100 people, so results may not hold in larger groups. Statins can affect the liver, and participants need careful monitoring.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
100 people
The number who actually took part.
- Started
-
Jun 2022
- Finished
-
Feb 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Admissibility measures were age ranged from 18 to 75, with a medical diagnosis of decompensated liver cirrhosis built on standard clinical symptoms, laboratory tests, imaging appearances and/or liver biopsy. Decompensation of the disease was labeled by to the lowest degree having one episode of severe complications, including ascites, SBP, jaundice, EGVB and HE.8 All participants were ready to be enrolled and had signed up the informed consent. The foremost exclusion criteria involved the following: (1) life-deadly leukocytopenia (WBCs \< 1 × 109/l); (2) Pregnant women or lactating mother; (3) patients diagnosed to have primary or secondary liver cancer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Decompensated liver cirrhosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta University
Tanta, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart Disease's hidden toll: study tracks quality of life across mind, body, and spirit
- 150,000 children to be tracked from birth to old age in massive health study
- Can a website help liver cancer patients care for themselves during chemoembolization?
- A 10-Question survey could give brazilian pulmonary hypertension patients a voice in their care
- Fewer dialysis sessions: can Twice-Weekly work as well?
- Two ways to rebuild a tongue: which one leaves patients better off?